Search
Ionis Pharmaceuticals Inc
IONSAdd to Watchlist
76.520USD
+0.530+0.70%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
12.69BMarket Cap
LossP/E TTM
More Details of Ionis Pharmaceuticals Inc Company
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ionis Pharmaceuticals Inc Info
Ticker SymbolIONS
Company nameIonis Pharmaceuticals Inc
IPO dateMay 17, 1991
CEOMonia (Brett P)
Number of employees1069
Security typeOrdinary Share
Fiscal year-endMay 17
Address2855 Gazelle Court
CityCARLSBAD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92010
Phone17609319200
Websitehttps://www.ionis.com/
Ticker SymbolIONS
IPO dateMay 17, 1991
CEOMonia (Brett P)
Company Executives of Ionis Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.66K
--
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
67.50K
+1.34%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
62.21K
-16.31%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
59.86K
-9.71%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
32.68K
+0.61%
Mr. Kyle Jenne
Mr. Kyle Jenne
Executive Vice President, Chief Global Product Strategy Officer
Executive Vice President, Chief Global Product Strategy Officer
23.71K
+30.89%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
242.66K
--
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
82.66K
-60.76%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
67.50K
+1.34%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
62.21K
-16.31%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
59.86K
-9.71%
FAQs
Who are the top five shareholders of Ionis Pharmaceuticals Inc?
The top five shareholders of Ionis Pharmaceuticals Inc are: Dr. Brett P. Monia, Ph.D.
How many institutions hold shares of Ionis Pharmaceuticals Inc (IONS)?
As of 2026Q1, 942 institutions hold shares of Ionis Pharmaceuticals Inc, with a combined market value of approximately 197.51M, accounting for 119.51% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 12089606.00.
What is the biggest source of revenue for Ionis Pharmaceuticals Inc?
In 2026Q1, the R&D revenue under collaborative agreements business generated the highest revenue for Ionis Pharmaceuticals Inc, amounting to 364.56M and accounting for 49.99% of total revenue.
